Company: DVAX
Filing Date: 2025-05-07
Form Type: DEFA14A
Source: 0000930413-25-001671
Chunk: 4

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-07
Form: DEFA14A
Chunk 4
---
 nominees who want to effectuate an outsized capital return and shutter efforts to accelerate growth with internal
and external opportunities. This plan would destroy the future value of our business and jeopardize the long-term potential of your investment.

Our Board and management team remain focused on what
matters most – working to deliver record results and sustained growth in 2025 and beyond.

Thank you for your continued support,

The Dynavax Board of Directors

Advisors

Goldman Sachs & Co. LLC is serving as financial advisor
to Dynavax and Cooley LLP is serving as legal counsel.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing
and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products,
HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), which is approved in the U.S., the European
Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years
of age and older, and CpG 1018 adjuvant,

Page 3 of 6

currently used in HEPLISAV-B and multiple adjuvanted COVID-19
vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

Forward-Looking Statements

This communication contains “forward-looking” statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking
statements. Forward-looking statements can generally be identified by the use of words such as “believe,” “continue,”
“estimate,” “expect,” “will,” “plan,” “potential,” “would”
and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking statements made in this document
include statements regarding expected contributions from our current directors, expectations regarding delivering value for our
stockholders, our future growth, potential of our differentiated technology, the timing of initiation and completion of clinical
trials and expected results, market share and size of the market, expected product revenue, our business strategy and long-term
performance. Actual results may differ materially from those set forth in this communication due to the risks and uncertainties
inherent in our business, including,